20:12 , Apr 5, 2019 |  BC Week In Review  |  Clinical News

Astellas' fezolinetant headed for Phase III

Astellas plans to start Phase III testing this year of fezolinetant to treat vasomotor symptoms in postmenopausal women after reporting that the therapy met the four co-primary endpoints in a Phase IIb trial. Astellas Pharma...
19:06 , Jan 4, 2019 |  BC Week In Review  |  Financial News

Venture roundup: Cabaletta, Thousand Oaks, Sojournix

Autoimmune company Cabaletta Bio Inc. (Radnor, Pa.), CMC services play Thousand Oaks Biopharmaceuticals Inc. (Haimen, China) and women's health company Sojournix Inc. (Waltham, Mass.) each announced venture rounds of at least $44 million on Jan....
22:05 , Jan 3, 2019 |  BC Extra  |  Financial News

Venture roundup: Cabaletta, Thousand Oaks, Sojournix

Autoimmune company Cabaletta Bio Inc. (Radnor, Pa.), CMC services play Thousand Oaks Biopharmaceuticals Inc. (Haimen, China) and women's health company Sojournix Inc. (Waltham, Mass.) each announced venture rounds of at least $44 million on Thursday....
18:06 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Longitude joins syndicate for women's health play KaNDy's £25M series C

KaNDy Therapeutics Ltd. (Stevenage, U.K.) raised £25 million ($31.9 million) in a series C round on Aug. 29. New investor Longitude Capital joined existing investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and...
20:59 , Aug 29, 2018 |  BioCentury  |  Finance

Sweetening the pot

KaNDy Therapeutics Ltd. believes its first venture round as an independent company will fund development of a non-hormonal therapy for menopausal symptoms that will be ready for a Phase III trial by 2020. Longitude Capital...
06:00 , Aug 29, 2018 |  BC Extra  |  Financial News

Longitude joins syndicate for women's health play KaNDy's £25M series C

KaNDy Therapeutics Ltd. (Stevenage, U.K.) raised £25 million ($31.9 million) in a series C round. New investor Longitude Capital joined existing investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed in the...
23:28 , Jun 7, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: May 2018

New Therapeutic Targets and Biomarkers: May 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during May 2018. Therapeutic targets are defined as any protein, gene or other...
18:49 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies suggest inhibiting the NK3R-TAC1 interaction could help treat social isolation syndrome. In a mouse model of social isolation syndrome, a tool compound NK3R inhibitor or shRNA targeting TAC1 decreased aggression and...
19:02 , May 25, 2018 |  BC Week In Review  |  Company News

Astellas unveils new R&D strategy

Astellas Pharma Inc. (Tokyo:4503) President and CEO Kenji Yasukawa, who took the reins in April, unveiled his 2018 strategic plan for the company May 22, including a shift in R&D focus and restructuring of Japan...
23:05 , May 22, 2018 |  BC Extra  |  Company News

Astellas unveils new R&D strategy

Astellas Pharma Inc. (Tokyo:4503) President and CEO Kenji Yasukawa, who took the reins in April, unveiled his 2018 strategic plan for the company Tuesday, including a restructuring of R&D and Japan operations. The pharma anticipates...